Concourse Financial Group Securities’s Marker Therapeutics MRKR Stock Holding History

Concourse Financial Group Securities’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2	Closed	-$36	–	2221
2020 Q2	$0	Hold	2	–	–	﹤0.01%	2189
2020 Q1	$0	Hold	2	–	–	﹤0.01%	2253
2019 Q4	$0	Buy	+2	New	+$73	﹤0.01%	2101
2019 Q3	–	Sell	-2	Closed	-$118	–	2000
2019 Q2	$0	Hold	2	–	–	﹤0.01%	2340
2019 Q1	$0	Hold	2	–	–	﹤0.01%	2351
2018 Q4	$0	Buy	+2	New	+$146	﹤0.01%	2191

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Concourse Financial Group Securities's MRKR Position: Q3 2020 in Review

Concourse Financial Group Securities sold out of Marker Therapeutics (MRKR) in Q3 2020, closing a stake of 2 shares — an estimated $36 sold.

Concourse Financial Group Securities first reported a position in MRKR in Q4 2018 and held it in 6 quarters. The position peaked at $0 in Q2 2020. 58 funds tracked by Wall St. Rank hold MRKR as of Q3 2020.

Concourse Financial Group Securities reported no remaining Marker Therapeutics position as of Q3 2020 after selling out during the quarter.
Concourse Financial Group Securities sold 2 Marker Therapeutics shares in Q3 2020, an estimated $36.
Concourse Financial Group Securities first reported a position in Marker Therapeutics in Q4 2018 and held it in 6 quarters.
Concourse Financial Group Securities's Marker Therapeutics position peaked at $0 in Q2 2020.
58 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2020.

Based on Concourse Financial Group Securities's 13F filing for Q3 2020, filed 13 Nov 2020.